Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function.
Ngoc T VuMinjung KimDaniel J StephensonH Patrick MacknightCharles E ChalfantPublished in: Molecular cancer research : MCR (2022)
Our findings depict how CERK inhibition may serve as a new key point in combination therapeutic strategy for NSCLC, specifically precision therapeutics targeting NSCLC possessing a KRAS mutation.